Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14343273 | 1.00 | OPRM1 (0.36) | OPRM1CHRM3TSHRALOX15ATM | |
| SCHEMBL7380300 | 0.79 | ELANE (0.31) | OPRM1GPR119 | |
| SCHEMBL10469218 | 0.79 | LMNA (0.41) | OPRM1CHRM3TSHRMEN1KMT2A | |
| SCHEMBL10575335 | 0.79 | LMNA (0.41) | OPRM1CHRM3TSHRMEN1KMT2A | |
| SCHEMBL10572588 | 0.79 | DDB1 (0.41) | OPRM1 | |
| SCHEMBL7378927 | 0.79 | DDB1 (0.41) | OPRM1 | |
| SCHEMBL14343367 | 0.78 | P4HB (0.32) | OPRM1GPR119 | |
| SCHEMBL7379886 | 0.77 | HRH3 (0.46) | TACR1OPRD1OPRK1 | |
| SCHEMBL17476067 | 0.76 | MEN1 (0.46) | OPRM1CHRM3TSHRMEN1KMT2A | |
| SCHEMBL16398618 | 0.76 | HSD11B1 (0.35) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-9655900-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9388195-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8933069-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8921354-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8722660-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | OPRM1 3189/4885CHRM3 4705/4885TSHR 3819/4885 |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | OPRM1 3189/4885CHRM3 4705/4885TSHR 3819/4885 |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | OPRM1 3189/4885CHRM3 4705/4885TSHR 3819/4885 |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | OPRM1 3189/4885CHRM3 4705/4885TSHR 3819/4885 |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | OPRM1 3189/4885CHRM3 4705/4885TSHR 3819/4885 |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | OPRM1 3189/4885CHRM3 4705/4885TSHR 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.